Találati lista | Tudóstér

001-es BibID:	BIBFORM101208
035-os BibID:	(cikkazonosító)846248 (WoS)000788361300001 (Scopus)85128359299
Első szerző:	Szebeni Gábor János (Szeged)
Cím:	Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls : a Single Center Study / Gábor J. Szebeni, Nikolett Gémes, Dániel Honfi, Enikő Szabó, Patrícia Neuperger, József Á. Balog, Lajos I. Nagy, Zoltán Szekanecz, László G. Puskás, Gergely Toldi, Attila Balog
Dátum:	2022
ISSN:	1664-3224
Megjegyzések:	Background: Vaccine-induced immunity is essential for controlling the COVID-19 pandemic. Data on humoral and cellular immunogenicity and safety of different SARSCoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases (RMDs) are limited. Methods: A single center observational study evaluated the immunogenicity and safety of the two-dose regimen of the BBIBP-CorV inactivated, Gam-COVID-Vac and AZD1222 adenovirus-based, and BNT162b2 and mRNA-1273 mRNA-based vaccines in patients with RMDs (n = 89) compared with healthy controls (n = 74). Neutralizing anti-RBD (receptor binding domain) specific antibodies and SARS-CoV-2 specific T-cell response were measured one and four months after the second vaccine dose in parallel with vaccination efficacy and safety. Results: Disease-specific comparison showed that antibody response at four months was higher in spondylarthropathies compared to rheumatoid arthritis and autoimmune RMDs. Risk factors for reduced immunogenicity included longer disease duration, positive immunoserological profile and anti-CD20 therapy of patients. The rate of positive antiRBD antibody response for healthy controls versus patients after 4 months post Frontiers in Immunology \| www.frontiersin.org 1 March 2022 \| Volume 13 \| Article 846248 Edited by: Laura Maggi, Università degli Studi di Firenze, Italy Reviewed by: Javier Carbone, Gregorio Maraño? n Hospital, Spain Ferenc Uher, Central Hospital of Southern Pest, Hungary *Correspondence: Ga? bor J. Szebeni szebeni.gabor@brc.hu Attila Balog balog.attila@med.u-szeged.hu ? These authors have contributed equally to this work and share first authorship ? These authors share senior authorship Specialty section: This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology Received: 30 December 2021 Accepted: 04 March 2022 Published: 31 March 2022 Citation: Szebeni GJ, Ge? mes N, Honfi D, Szabo? E, Neuperger P, Balog JA?, Nagy LI, Szekanecz Z, Puska? s LG, Toldi G and Balog A (2022) Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. Front. Immunol. 13:846248. doi: 10.3389/fimmu.2022.846248 ORIGINAL RESEARCH published: 31 March 2022 doi: 10.3389/fimmu.2022.846248 vaccination was 69% vs. 55% for the inactivated viral vaccine BBIBP-CorV, 97% vs. 53% for the pooled data of adenovirus vector-based vaccines Gam-COVID-Vac and AZD1222, or 100% vs. 81% for the pooled data of mRNA vaccines BNT162b2 and mRNA-1273, respectively. Patients who received the Gam-COVID-Vac or mRNA-1273 vaccines had a higher proportion of TNF-a producing CD4+ T-cells upon SARS-CoV-2 antigen stimulation compared to the inactivated viral vaccine. Conclusion: All five investigated vaccines were immunogenic in the majority of patients and healthy controls with variable antibody and T-cell response and an acceptable safety profile.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk SARS-CoV-2 vaccination rheumatic and musculoskeletal diseases anti-RBD neutralizing antibodies CD4+ T-cell response CD8+ T-cell response
Megjelenés:	Frontiers in Immunology. - 13 (2022), p. 1-11. -
További szerzők:	Gémes Nikolett Honfi Dániel Szabó Enikő Neuperger Patrícia Balog József A. Nagy Lajos István (Szeged) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Puskás László G. Toldi Gergely Balog Attila
Pályázati támogatás:	2020-1.1.6-JÖVŐ-2021- NKFIH
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: